- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Corticotropin injection is indicated for diagnostic testing of adrenocortical function.
Corticosteroid therapy is considered the treatment of choice in conditions responsive to corticosteroids. Corticotropin may be used as an alternative to corticosteroids in the following conditions:
Nonsuppurative thyroiditis; Hypercalcaemia associated with cancer
Nervous System Disorders:
Acute exacerbations of multiple sclerosis
Adjunctive therapy for short-term administration in acute exacerbations of:
Psoriatic arthritis; rheumatoid arthritis ( including juvenile rheumatoid arthritis); ankylosing spondylitis; acute and subacute bursitis; acute non-specific tenosynovitis; acute gouty arthritis; post-traumatic arthritis; synovitis of osteoarthritis; epicondylitis
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus; Systemic dermatomyositis (polymyositis); Acute rheumatic carditis
Pemphigus; Bullous dermatitis herpetiformis; Severe erythema multiforme (Stevens-Johnson Syndrome); Exfoliative dermatitis; Severe psoriasis; Severe seborrhoeic dermatitis; Mycosis fungoides
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis; Bronchial asthma; Contact dermatitis; Atopic dermatitis; Serum sickness
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic conjunctivitis; Keratitis; Herpes zoster ophthalmicus; iritis and iridocyclitis; Diffuse posterior uveitis and choroiditis; Optic neuritis; Sympathetic ophthalmia; Chorioretinitis; Anterior segment inflammation; Allergic corneal marginal ulcers
Symptomatic sarcoidosis; Loeffler's syndrome uncontrollable by other means; Berylliosis; Fulminating or disseminated pulmonary tuberculosis (with anti-TB chemotherapy); Aspiration pneumonitis
Autoimmune haemolytic anaemia; Secondary thrombocytopaenia in adults; Erythroblastopenia; Congenital hypoplastic anaemia
Palliative management of:
Leukaemias and lymphomas in adults; Acute leukaemia in children
To induce diuresis or remission of proteinuria in nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythmatosus
During the critical period of: Ulcerative colitis; Regional enteritis
Tuberculous meningitis with subarachnoid block or impending block (with appropriate anti-TB chemotherapy); Trichinosis with neurologic or myocardial involvement
DosageStandard tests for verification of adrenal responsiveness to corticotropin using the route(s) of administration proposed for treatment should be performed prior to initiation of treatment. A rise in urinary and plasma corticosteroid values provides evidence of a stimulatory effect.
Dosage should be individualised according to the disease being treated and the general medical condition of the patient. Frequency of administration and dose should be determined according to disease severity, plasma and urine corticosteroid levels and initial response of the patient.
Any changes to dosage schedules should be made gradually and only after the full effects of the drug have become apparent.
Treatment of acute exacerbations of multiple sclerosis:
80 to 120 units may be administered daily by intramuscular injection for a period of 2 to 3 weeks.
Treatment of acute gouty arthritis:
Treatment should be limited to a few days as there is a risk of rebound attacks when corticotropin is discontinued. Conventional concomitant therapy should be given during treatment and for several days after.
Prolonged use in children will inhibit skeletal growth. If the use of corticotropin is necessary in children, it should be given intermittently and the child should be carefully monitored.
Patients with Renal Impairment
Corticotropin should be used with caution in patients with renal impairment as it may exacerbate the condition.
Patients with Hepatic Impairment
Corticotropin produces an enhanced effect in patients with hepatic impairment, therefore caution is advised in these patients.
Additional Dosage Information
Chronic administration of doses greater than 40units daily may be associated with uncontrollable adverse effects.
If reduction in dosage is indicated, it should be done gradually by either reducing the amount of each injection, administering injections at longer intervals or by a combination of both, with careful monitoring of the patient and the disease throughout.
Precautions and Warnings
Corticotropin injection is not licensed in the UK. Both the patient and professional should be aware that this is an unlicensed product.
Treatment should not be initiated until adrenal responsiveness has been verified using the chosen route of administration for treatment (see 'Dosage' section).
Corticotropin injection should be used at the lowest effective dose for the shortest period of time required to accomplish the therapeutic goal. It suppresses the symptoms without altering the progression of the disease.
Pregnancy - see 'Pregnancy' section.
Use with caution in patients with hypothyroidism or those with hepatic impairment as an enhanced effect will be seen in these patients.
If corticotropin is required in patients where infection is present, appropriate antibiotic therapy be be administered. Caution is advised in patients with latent tuberculosis and close observation is recommended. If treatment is prolonged, chemoprophylaxis should be initiated.
Corticotropin may increase the susceptibility to infections and their severity through suppression of the inflammatory response and immune function. The clinical presentation of infections may be atypical and serious infections may be masked and may reach an advanced stage before being recognised. New infections, including fungal and viral infections of the eye, may develop during treatment.
Corticotropin injection should be used with caution in patients with diabetes melitis, renal impairment, diverticulitis and myasthenia gravis as these conditions may be exacerbated by administration of corticotropin.
Precipitation of psychiatric disturbances is possible with corticotropin use and it should be used with caution in patients with a history of psychiatric disturbances as corticotropin may exacerbate existing symptoms. This may range from mood alteration to a psychotic state.
Live vaccines should be avoided in patients receiving corticotropin. Other immunisations should be undertaken cautiously due to the possible hazards of neurological complications and the lack of antibody response.
Corticotropin may depress the hypothalamic-pituitary-adrenal axis and therefore abrupt withdrawal may produce adrenocortical and pituitary unresponsiveness. Consequently, withdrawal or dose reduction should be done gradually. An increase in corticosteroid requirements associated with stress, infection, surgery or trauma may also precipitate acute adrenocortical insufficiency and the use of rapidly acting corticosteroids before, during and after unusually stressful situations is indicated in patients on prolonged therapy. Corticotropin should not be withdrawn suddenly in patients who have received prolonged therapy as this may lead to recurrent symptoms. Doses should be tapered and the injection interval increased to gradually withdraw the drug.
Corticotropin should be avoided in patients where disease is accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction.
Chronic administration of corticotropin may lead to irreversible adverse effects and also increases the risk of hypersensitivity reactions.
Prolonged administration of corticotropin may cause subcapsular cataracts and glaucoma, with possible damage to the optic nerves.
Sodium and water retention can occur with the use of corticotropin and dietary salt restriction may be required. Potassium loss can also occur which may require supplementation. An increase in calcium excretion may also be seen.
Use with caution in children under 18 years as prolonged use has been shown to inhibit skeletal growth ( see 'Dosage - Children' ).
Pregnancy and Lactation
Manufacturer advises that corticotropin has been shown to have an embryocidal effect although there is no published information on adequate, well-controlled studies in pregnant women at the time of writing. Corticotropin should only be used during pregnancy if the potential benefit to the mother outweighs the potential risk to the foetus.
Studies reporting use in pregnancy have not demonstrated adverse foetal effects although corticosteroid use in pregnancy has been suspected of causing malformations. Since corticotropin stimulates the release of endogenous corticosteroids, this relationship should be considered when prescribing to women of child-bearing potential.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password at https://www.toxbase.org/
It is not known whether corticotropin is excreted in breast milk as there is no published experience concerning the use of corticotropin during breastfeeding at the time of writing. Manufacturer recommends that because of the potential risk of adverse reactions in the infant, a decision should be made to either discontinue breast-feeding or to discontinue corticotropin, considering the requirements of the mother.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Increased calcium excretion
Reduced muscle mass
Vertebral compression fractures
Vertebral and long bone fractures
Peptic ulceration with perforation and haemorrhage
Wound healing retarded
Thinning of skin
Suppression of reactions to skin tests
Hyperpigmentation of skin
Congestive cardiac failure
Raised intracranial pressure
Suppression of growth in children and adolescents
Secondary adrenocortical and pituitary unresponsiveness
Impaired carbohydrate tolerance, increased need for anti-diabetic therapy
Precipitation of diabetes
Posterior subcapsular cataracts
Increased intra-ocular pressure
Optic nerve damage
Negative nitrogen balance
Allergic skin reactions
Increased susceptibility and severity of infections
Suppression of clinical signs of infection
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111.
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet (https://www.toxbase.org/).
Shelf Life and Storage
Store at 2 - 8 degrees C
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.